Bridgeway Capital Management LLC Trims Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Bridgeway Capital Management LLC trimmed its stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 4.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,064 shares of the company’s stock after selling 5,000 shares during the period. Bridgeway Capital Management LLC owned about 0.24% of Vigil Neuroscience worth $170,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Northern Trust Corp raised its position in Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock valued at $110,000 after acquiring an additional 14,572 shares in the last quarter. Barclays PLC raised its position in Vigil Neuroscience by 43.6% during the fourth quarter. Barclays PLC now owns 64,049 shares of the company’s stock valued at $109,000 after acquiring an additional 19,436 shares in the last quarter. Jane Street Group LLC purchased a new position in Vigil Neuroscience during the fourth quarter valued at approximately $83,000. Marshall Wace LLP raised its position in Vigil Neuroscience by 85.3% during the fourth quarter. Marshall Wace LLP now owns 266,895 shares of the company’s stock valued at $454,000 after acquiring an additional 122,853 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in Vigil Neuroscience during the fourth quarter valued at approximately $249,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Vigil Neuroscience Price Performance

Vigil Neuroscience stock opened at $2.52 on Wednesday. The stock has a market capitalization of $117.61 million, a PE ratio of -1.22 and a beta of 1.90. Vigil Neuroscience, Inc. has a 12 month low of $1.31 and a 12 month high of $6.06. The business has a 50 day simple moving average of $1.94 and a 200-day simple moving average of $2.29.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. On average, equities research analysts anticipate that Vigil Neuroscience, Inc. will post -2.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on VIGL. Wedbush reiterated an “outperform” rating and set a $13.00 price target on shares of Vigil Neuroscience in a research report on Monday, May 5th. HC Wainwright reduced their price target on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, March 14th. William Blair upgraded Vigil Neuroscience to a “strong-buy” rating in a research report on Thursday, April 24th. Finally, Guggenheim restated a “buy” rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.